A5012912643- Amyloidosis: Diagnosis, Treatment, Outcomes
- Acute Myeloid Leukemia Research
- Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Oral and Maxillofacial Pathology
- Tumors and Oncological Cases
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Medical Imaging and Pathology Studies
- Head and Neck Cancer Studies
- DNA Repair Mechanisms
- Dermatological and Skeletal Disorders
- Microtubule and mitosis dynamics
- Sarcoma Diagnosis and Treatment
- Protein Degradation and Inhibitors
- Acute Lymphoblastic Leukemia research
- Neuroendocrine Tumor Research Advances
- Chronic Lymphocytic Leukemia Research
- Epigenetics and DNA Methylation
- Cancer-related Molecular Pathways
- Retinoids in leukemia and cellular processes
- Cancer Treatment and Pharmacology
- Parathyroid Disorders and Treatments
National Center for Tumor Diseases
2015-2024
German Cancer Research Center
2015-2024
Heidelberg University
2015-2024
University Hospital Heidelberg
2014-2024
DKFZ-ZMBH Alliance
2017-2024
German Center for Lung Research
2019-2023
Molecular Oncology (United States)
2017-2018
Deutschen Konsortium für Translationale Krebsforschung
2018
Amyloidosis Foundation
2008-2017
Chirurgische Universitätsklinik Heidelberg
2014-2015
Bortezomib has become a cornerstone in the treatment of AL amyloidosis. In this study, we addressed prognostic impact cytogenetic aberrations for bortezomib-treated patients.We analyzed consecutive series 101 patients with amyloidosis treated bortezomib-dexamethasone as first-line by interphase fluorescence situ hybridization (iFISH). Patients were ineligible high-dose chemotherapy, which would put them at risk cardiac or renal failure, and thus represented poor-risk group.Presence t(11;14),...
First reported in 1999, germline runt-related transcription factor 1 (RUNX1) mutations are a well-established cause of familial platelet disorder with predisposition to myeloid malignancy (FPD-MM). We present the clinical phenotypes and genetic detected 10 novel RUNX1-mutated FPD-MM families. Genomic analyses on these families 2 partial gene deletions, 3 mutations, 5 recurrent as RUNX1 alterations leading FPD-MM. Combining genomic data from herein aggregated published sets resulted 130...
A complex aberrant karyotype consisting of multiple unrelated cytogenetic abnormalities is associated with poor prognosis in patients acute myeloid leukemia (AML). The European Leukemia Net classification and the UK Medical Research Council recommendation provide prognostic categories that differ definition unbalanced aberrations as well number single aberrations. aim this study on 3526 AML was to redefine validate a cutoff for complexity regard adverse prognosis. Our demonstrated (1) pure...
CUPISCO is an ongoing randomized phase II trial (NCT03498521) comparing molecularly guided therapy versus platinum-based chemotherapy in patients newly diagnosed with "unfavorable" cancer of unknown primary (CUP).Patients unfavorable CUP diagnosis, as defined by the European Society Medical Oncology (ESMO), and available tissue for molecular sequencing are generally eligible. Potential entering screening undergo a review involving reference histopathology clinical work-up central eligibility...
Chromosomal aberrations of plasma cells are well established pathogenetic and prognostic factors in multiple myeloma, but their implication systemic light chain (AL) amyloidosis is unclear. Therefore, the aim this study was to identify cytogenetic risk by interphase FISH a series 103 consecutive AL patients treated uniformly with melphalan/dexamethasone as first-line therapy. Detection gain 1q21 predictive for poor overall survival (OS) (median 12.5 versus 38.2 months, p = 0.002)....
Allogeneic hematopoietic cell transplantation (alloHCT) as a postremission therapy in patients with FLT3-ITD-positive intermediate-risk acute myeloid leukemia (AML) remains controversial. FLT3-ITD mutations are heterogeneous respect to allelic ratio, location, and length of the insertion, high mutant-to-wild-type ratio consistently associated inferior prognosis. We retrospectively analyzed role alloHCT first remission relationship presence or absence nucleophosmin 1 (NPM1) Study Alliance...
The objective was to evaluate the prognostic impact of pre-transplant minimal residual disease (MRD) as determined by real-time quantitative polymerase chain reaction in 67 adult NPM1-mutated acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Twenty-eight had a FLT3-ITD (42%). Median age at 54.7 years, median follow-up for survival from time allografting 4.9 years. At transplantation, 31 were first, 20 second complete remission (CR) and 16...
Abstract Cancer of unknown primary has a dismal prognosis, especially following failure platinum-based chemotherapy. 10-20% patients have high tumor mutational burden (TMB), which predicts response to immunotherapy in many cancer types. In this prospective, non-randomized, open-label, multicenter Phase II trial (EudraCT 2018-004562-33; NCT04131621), relapsed or refractory after chemotherapy received nivolumab and ipilimumab TMB vs. low stratification. Progression-free survival (PFS)...
In acute myeloid leukemia (AML), studies based on whole-genome sequencing have shown genomic diversity within leukemic clones. The aim of this study was to address clonal heterogeneity in AML metaphase cytogenetics.This analysis included all patients enrolled onto two consecutive, prospective, randomized multicenter trials the Study Alliance Leukemia. Patients were newly diagnosed with non-M3 and fit for intensive chemotherapy.Cytogenetic subclones detected 418 (15.8%) 2,639 from whole...
Oncogenic gene fusions are important drivers in many cancer types, including carcinomas, with diagnostic and therapeutic implications. Hence, sensitive rapid methods for parallel profiling formalin-fixed paraffin-embedded (FFPE) specimens needed. In this study we analyzed a cohort of 517 cases where standard treatment options were exhausted. To end the Archer® DX Solid tumor panel (AMP; 285 cases) Oncomine Comprehensive Assay v3 (OCA; 232 employed. Findings validated by Sanger sequencing,...